Retatrutide, the triple agonist, showed large weight loss in phase 2

It acts on GIP, GLP-1 and glucagon receptors at once; the effect was dose-dependent at 48 weeks.

Retatrutide is the first molecule of its kind to activate three metabolic receptors: GIP, GLP-1 and glucagon. In this phase 2 trial, adults with obesity received different weekly doses or placebo for 48 weeks.

Weight reduction was substantial and dose-dependent, and the most frequent adverse events were gastrointestinal. These results led to the TRIUMPH phase 3 programme, now under way.

In three points

Phase 2 human trial, 48 weeks
First GIP / GLP-1 / glucagon triple agonist
Opened the TRIUMPH phase 3 programme

Compounds mentioned

Retatrutide

Original source: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine

Plain-language summary by SYNTRA LABS based on the original publication and checked against its source. It is not medical advice or a recommendation for use. SYNTRA LABS compounds are for research use only and not for human consumption.